Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis—a critical review of its pathogenesis and treatment
JC McMurray, JW May, MW Cunningham… - Frontiers in …, 2020 - frontiersin.org
MIS-C is a newly defined post-viral myocarditis and inflammatory vasculopathy of children
following COVID-19 infection. This review summarizes the literature on diagnosis …
following COVID-19 infection. This review summarizes the literature on diagnosis …
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS
Current literature addressing the pharmacological principles guiding glucocorticoid (GC)
administration in ARDS is scant. This paucity of information may have led to the …
administration in ARDS is scant. This paucity of information may have led to the …
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
MA Matthay, BT Thompson - The Lancet Respiratory Medicine, 2020 - thelancet.com
The impressive results of the RECOVERY trial established that a moderate dose of
dexamethasone (6 mg daily for 10 days) reduced mortality in hospitalised patients with …
dexamethasone (6 mg daily for 10 days) reduced mortality in hospitalised patients with …
The current status of drug repositioning and vaccine developments for the COVID-19 pandemic
Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world
has vehemently worked to develop treatments and vaccines against severe acute …
has vehemently worked to develop treatments and vaccines against severe acute …
Systematic review on the therapeutic options for COVID-19: clinical evidence of drug efficacy and implications
Abstract A novel coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China, and
quickly spread globally. Several treatments have been proposed, many of which have …
quickly spread globally. Several treatments have been proposed, many of which have …
[HTML][HTML] The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
The recent finding of the effectiveness of corticosteroid therapy in reducing mortality in
patients with severe coronavirus disease-19 (COVID-19) is a welcome breakthrough [1, 2, 3 …
patients with severe coronavirus disease-19 (COVID-19) is a welcome breakthrough [1, 2, 3 …
Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: a systematic review and meta-analysis
S Alhumaid, A Al Mutair, Z Al Alawi, N Alhmeed… - Tropical medicine and …, 2020 - mdpi.com
(Background) Lopinavir-ritonavir (LPV/RTV) is a human immunodeficiency virus (HIV)
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …
Can natural polyphenols help in reducing cytokine storm in COVID-19 patients?
G Giovinazzo, C Gerardi, C Uberti-Foppa, L Lopalco - Molecules, 2020 - mdpi.com
SARS-CoV-2 first emerged in China during late 2019 and rapidly spread all over the world.
Alterations in the inflammatory cytokines pathway represent a strong signature during SARS …
Alterations in the inflammatory cytokines pathway represent a strong signature during SARS …
Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19
Producing and using timely comparative evidence on drugs: lessons from clinical trials for
covid-19 Page 1 Producing and using timely comparative evidence on drugs: lessons from …
covid-19 Page 1 Producing and using timely comparative evidence on drugs: lessons from …
[HTML][HTML] SARS‐CoV‐2 virus infection: targets and antiviral pharmacological strategies
DM de Oliveira Campos, UL Fulco… - Journal of evidence …, 2020 - ncbi.nlm.nih.gov
The current pandemic of coronavirus disease 2019 (COVID-19) poses a threat to global
public health owing to its high rate of spread and its association with severe forms of …
public health owing to its high rate of spread and its association with severe forms of …